{"id":"NCT05360784","sponsor":"Bausch & Lomb Incorporated","briefTitle":"\"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness\"","officialTitle":"The Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation With Lumify® 0.025% in Adult Subjects With Ocular Redness","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-13","primaryCompletion":"2022-11-23","completion":"2022-11-23","firstPosted":"2022-05-04","resultsPosted":"2024-08-26","lastUpdate":"2024-08-26"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ocular Redness"],"interventions":[{"type":"DRUG","name":"Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation","otherNames":[]},{"type":"DRUG","name":"Lumify® (brimonidine tartrate ophthalmic solution 0.025%)","otherNames":[]}],"arms":[{"label":"Brimonidine tartrate preservation-free","type":"EXPERIMENTAL"},{"label":"Lumify®","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites. Participants with ocular redness will be randomized to receive either brimonidine tartrate ophthalmic solution 0.025%, preservative-free formulation, or Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will be treated with study drug for approximately 4 weeks.","primaryOutcome":{"measure":"Ocular Redness","timeFrame":"Assessed at 5, 15, 30, 60, 90,120,180, 240 minutes post instillation.","effectByArm":[{"arm":"Brimonidine Tartrate Preservation-free","deltaMin":0.46,"sd":0.039},{"arm":"Lumify®","deltaMin":0.53,"sd":0.041}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["40711722"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":188},"commonTop":["Instillation site pain","Sinusitis","Covid 19","Visual acuity reduced"]}}